Latest Insider Transactions at Biogen Inc. (BIIB)
This section provides a real-time view of insider transactions for Biogen Inc. (BIIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOGEN INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOGEN INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
252
+10.76%
|
-
|
|
Jul 01
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
148
-6.55%
|
$31,080
$210.63 P/Share
|
|
Jul 01
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
504
+18.25%
|
-
|
|
Jun 15
2022
|
Alexander J Denner Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+8.32%
|
-
|
|
Jun 15
2022
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+5.57%
|
-
|
|
Jun 15
2022
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+38.98%
|
-
|
|
Jun 15
2022
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+24.64%
|
-
|
|
Jun 15
2022
|
William D /Ca/ Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+38.98%
|
-
|
|
Jun 15
2022
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+21.21%
|
-
|
|
Jun 15
2022
|
Richard Mulligan Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+8.32%
|
-
|
|
Jun 15
2022
|
Stelios Papadopoulos Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,255
+18.26%
|
-
|
|
Jun 15
2022
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+6.66%
|
-
|
|
Jun 15
2022
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,370
+6.9%
|
-
|
|
Apr 01
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-4.43%
|
$17,640
$210.65 P/Share
|
|
Apr 01
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
239
+11.19%
|
-
|
|
Feb 18
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
659
-1.45%
|
$137,731
$209.79 P/Share
|
|
Feb 18
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,485
+3.15%
|
-
|
|
Feb 18
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
616
-5.21%
|
$128,744
$209.79 P/Share
|
|
Feb 18
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,387
+10.49%
|
-
|
|
Feb 18
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
879
-10.66%
|
$183,711
$209.79 P/Share
|
|
Feb 18
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
1,981
+19.38%
|
-
|
|
Feb 18
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-9.07%
|
$36,575
$209.79 P/Share
|
|
Feb 18
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
594
+23.54%
|
-
|
|
Feb 18
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-6.31%
|
$24,453
$209.79 P/Share
|
|
Feb 18
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
396
+17.6%
|
-
|
|
Feb 18
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
977
-18.08%
|
$204,193
$209.79 P/Share
|
|
Feb 18
2022
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,981
+26.82%
|
-
|
|
Feb 18
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
110
-6.23%
|
$22,990
$209.79 P/Share
|
|
Feb 18
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
371
+17.35%
|
-
|
|
Feb 18
2022
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,746
-3.92%
|
$573,914
$209.79 P/Share
|
|
Feb 18
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,191
+8.12%
|
-
|
|
Feb 12
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-6.18%
|
$19,688
$214.59 P/Share
|
|
Feb 12
2022
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
263
+15.02%
|
-
|
|
Feb 12
2022
|
Michel Vounatsos Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,566
-4.15%
|
$1,833,124
$214.59 P/Share
|
|
Feb 12
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,716
+5.92%
|
-
|
|
Feb 12
2022
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
171
-3.71%
|
$36,594
$214.59 P/Share
|
|
Feb 12
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
275
+8.16%
|
-
|
|
Feb 12
2022
|
Rachid Izzar Head of Global Product Strat. |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-8.37%
|
$26,108
$214.59 P/Share
|
|
Feb 12
2022
|
Rachid Izzar Head of Global Product Strat. |
BUY
Exercise of conversion of derivative security
|
Direct |
351
+19.41%
|
-
|
|
Feb 12
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
SELL
Payment of exercise price or tax liability
|
Direct |
2,342
-10.34%
|
$501,188
$214.59 P/Share
|
|
Feb 12
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Exercise of conversion of derivative security
|
Direct |
2,597
+14.51%
|
-
|
|
Feb 12
2022
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-3.76%
|
$267,928
$214.59 P/Share
|
|
Feb 12
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,672
+6.99%
|
-
|
|
Feb 12
2022
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,056
-1.51%
|
$439,984
$214.59 P/Share
|
|
Feb 12
2022
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,280
+2.45%
|
-
|
|
Jan 19
2022
|
Michel Vounatsos Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,594
+14.27%
|
-
|
|
Jan 19
2022
|
Robin Kramer Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
244
+15.27%
|
-
|
|
Jan 19
2022
|
Chirfi Guindo Head of Glob Prod Strat & Com |
BUY
Grant, award, or other acquisition
|
Direct |
3,088
+33.95%
|
-
|
|
Jan 19
2022
|
Ginger Gregory EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,941
+16.22%
|
-
|
|
Jan 19
2022
|
Alphonse Galdes EVP Pharmaceutical Oper & Tech |
BUY
Grant, award, or other acquisition
|
Direct |
658
+11.5%
|
-
|